[1] RIDER A C, FRAZEE B W. Community-acquired pneumonia[J]. Emerg Med Clin North Am, 2018,36(4):665-683. [2] ZIFODYA J S, DUNCAN M S, SO-ARMAH K A, et al. Community-acquired pneumonia and risk of cardiovascular events in people living with HIV[J]. J Am Heart Assoc, 2020,9(23):e017645. [3] MRAK D, ZIERFUSS B, HÖBAUS C, et al. Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality[J]. Atherosclerosis, 2021,317(1):41-46. [4] 寇朴怀,苗建玲. 血清sCD14、sCD163水平与冠状动脉粥样硬化病变程度及稳定性的相关性[J]. 海南医学,2021,32(15):1915-1918. [5] BERNARDI S, VOLTAN R, RIMONDI E, et al. TRAIL, OPG and TWEAK in kidney disease: biomarkers or therapeutic targets?[J]. Clin Sci: Lond, 2019,133(10):1145-1166. [6] COMERTPAY E, VURAL S, EROĜLU O, et al. The diagnostic value of sTWEAK in acute ischemic stroke[J]. Balkan Med J, 2020,37(6):336-340. [7] 中华医学会呼吸病学分会.中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J].中华结核和呼吸杂志,2016,39(4):253-279. [8] 陈勇,陈宇,张娜,等.血液相关指标在社区获得性肺预后评估中的价值[J].中华医院感染学杂志,2019,29(23):3573-3576. [9] LIM W S, VAN DER EERDEN M M, LAING R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study[J]. Thorax, 2003,58(5):377-382. [10] FERREIRA-COIMBRA J, SARDA C, RELLO J. Burden of community-acquired pneumonia and unmet clinical needs[J]. Adv Ther, 2020,37(4):1302-1318. [11] VIOLI F, CANGEMI R, FALCONE M, et al. Cardiovascular complications and short-term mortality risk in community-acquired pneumonia[J]. Clin Infect Dis, 2017,64(11):1486-1493. [12] FELDMAN C, NORMARK S, HENRIQUES-NORMARK B, et al. Pathogenesis and prevention of risk of cardiovascular events in patients with pneumococcal community-acquired pneumonia[J]. J Intern Med, 2019,285(6):635-652. [13] PIERALLI F, VANNUCCHI V, NOZZOLI C, et al. Acute cardiovascular events in patients with community acquired pneumonia: results from the observational prospective FADOI-ICECAP study[J]. BMC Infect Dis, 2021,21(1):116-127. [14] 陈亮,韩秀迪,李艳丽,等.社区获得性肺炎住院病人发生心血管事件的危险因素分析[J].中华心血管病杂志,2020,48(3):228-235. [15] 张杰.肿瘤坏死因子样弱凋亡诱导因子通路在心力衰竭中的作用的研究进展[J].心血管病学进展,2017,38(2):159-162. [16] 叶静.ACS病人TpP、sCD163水平变化与冠脉病变严重程度的相关性分析[J].医学临床研究,2019,36(11):2254-2256. [17] 王磊,夏云峰,李良,等.心房颤动病人血清sCD14、sCD163的表达及临床意义[J].中西医结合心脑血管病杂志,2019,17(15):2348-2351. [18] MCMAHON M, SKAGGS B, GROSSMAN J, et al. Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE[J]. Lupus Sci Med, 2019,6(1):1-9. [19] 杜秋红,徐萍.血浆sTWEAK水平与ACS病人冠状动脉病变严重程度及预后的关系分析[J].中西医结合心脑血管病杂志,2019,17(4):557-559. [20] RUSU C C, RACASAN S, KACSO I M, et al. The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients[J]. Int Urol Nephrol,2015,47(12):2023-2030. |